CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

NP-120 (Ifenprodil)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug1497 Xiyanping injection Wiki 1.00
drug753 Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride Wiki 1.00

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.07
D018352 Coronavirus Infections NIH 0.05

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.07

There is one clinical trial.

Clinical Trials

1 A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Confirmed COVID-19 Infected Hospitalized Patients

The purpose of this adaptive trial is to determine the clinical efficacy of Ifenprodil in the treatment of patients infected with COVID-19. This Protocol is largely based on the recommendations of the WHO R&D Blueprint Clinical Trials Expert Group COVID-19 Therapeutic Trial Synopsis, and associated Master Protocol. The choice of the primary outcome measure will be determined by a pilot study of the first 100 subjects. Subject clinical status (on a 7-point ordinal scale) at day 15 in treatment versus the control group is the default primary endpoint.

NCT04382924 COVID Drug: NP-120 (Ifenprodil)

Primary Outcomes

Description: Not hospitalized, no limitations on activities Not hospitalized, limitation on activities Hospitalized, not requiring supplemental oxygen Hospitalized, requiring supplemental oxygen Hospitalized, on non-invasive ventilation or high flow oxygen devices Hospitalized, on invasive mechanical ventilation or ECMO Death

Measure: Patient clinical status (on the WHO 7-point ordinal scale) at day 15 in IP versus SOC control group patients:

Time: Day 15

Secondary Outcomes

Measure: Status on an ordinal scale assessed daily while hospitalized and on days 15 and 28 in IP versus control group patients

Time: Days 1 through 28

Measure: NEWS assessed days 3, 5, 8 ,11 daily while hospitalized and on days 15 and 29 in IP versus control group patients

Time: Days 3, 5, 8, 11, 25, 29

Measure: Rate of mechanical ventilation in IP versus control group patients

Time: Day 15, 28

Measure: Duration of mechanical ventilation (if applicable) in IP versus control group patients

Time: Day 15, 28

Measure: Duration of supplemental oxygen in IP versus control group patients

Time: Day 15, 28

Measure: Time to return to room pressure (SpO2 > 94%) on room air

Time: Day 15, 28

Measure: Duration in ICU (if applicable) in IP versus control group patients

Time: Day 15, 28

Measure: Rate of Mortality in IP versus control group patients

Time: Day 15, 28

Measure: Duration of hospitalization in IP versus control group patients

Time: Day 15, 28

Measure: Time to discharge in IP versus control group patients

Time: Day 15, 28

Measure: Effect on the rate of change of partial pressure of oxygen (PaO2) and PaO2/FiO2 ratio taken at baseline and measured once daily up to 2 weeks of treatment in IP versus control group patients

Time: Up to day 15, day 28

No related HPO nodes (Using clinical trials)